n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, October 4th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

GripeVine, Inc. (GRPV)

InvestorsHub, MarketWatch, InvestorsHangout, Morningstar, and Stockhouse reported on GripeVine, Inc. (GRPV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GripeVine, Inc. is a company concentrating on leading the revolution of social customer service. The Company is a proprietary complaint-resolution platform for the facilitation and management of social customer service via centralized communication, rating, and review tools. It has a highly scalable and sustainable growth model. Listed on the OTCQB, GripeVine has its headquarters in New York, New York.

GripeVine’s mission is to establish itself as a global leader in social consumer resolution and relationship management. It works to accomplish this through providing businesses strong tools to manage their social presence while providing consumers with tangible resolution results and a social engine.

High profiles companies and localized SME’s (small and medium-sized enterprises) use GripeVine. The Company speeds up the resolution process between consumers and businesses. Basically, GripeVine creates a fair space for business and consumers to interact.

GripeVine has a platform where, as the Company states, all sides can be heard. It has a user-friendly social CRM (Customer Relationship Management) platform for users to engage on. The focus is on turning negative experiences into positive outcomes.

The system incentivizes positive and amicable outcomes. Moreover, it rewards reliable consumers and responsive businesses. The emphasis is amicable or harmonious social customer service solutions for every business sector.

GripeVine provides a thriving social engine for consumers and premier back end tools for businesses. GripeVine is the next development in social customers’ relations. The Company is also the central hub of activity where businesses and consumers can be heard regarding their particular concerns. 

GripeVine develops, owns, and operates social customer relations applications on desktop and mobile computing platforms. The Company has innovative patents. These patents boost a flourishing community and provide businesses first-rate control over their social public image.

In late August 2017, Mr. Richard Hue, GripeVine Chief Executive Officer, announced the launch of GripeVine.com's new platform to meet the demands of the continuing changes in the landscape of "social customer service."

Mr. Hue added, "We've also taken the opportunity to completely rebrand GripeVine with our new logo and showcasing the full capabilities of responsive flat design incorporating an entirely new UI experience that contains the complexity of robust social customer service in a simple to engage platform."

GripeVine, Inc. (GRPV), closed Wednesday's trading session at $0.21, even for the day. The average volume for the last 60 days is 9,188 and the stock's 52-week low/high is $0.065/$1.60.

Medibio Limited (MDBIF)

OTC Markets, Stockhouse, 4-Traders, InvestorsHangout, and AwesomePennyStocks reported on Medibio Limited (MDBIF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Medibio Limited is a digital health company listed on the OTC Markets Group’s OTCQB. The Company has developed an objective testing system to assist in the screening, diagnosis, and treatment effectiveness of depression, chronic stress, and other mental health disorders. The test employs patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to help in clinical diagnosis. Medibio is headquartered in Sydney Australia.

The Company is on course to commercialize its platform technology called the Digital Mental Health Platform. The foundation of this is on patented biomarkers from the autonomic nervous system. Medibio’s technology will provide a Diagnosis Aid to assist General Practioners (GPs) and mental health clinicians.

Regarding biomarker based objective diagnosis, a panel of circadian, sleep, and automatic system biomarkers enables automated, repeatable, and objective characterization of the impact of mental illness on the physiologic state. The Company’s Digital Mental Health Platform is a device agnostic platform that can ingest data from numerous devices. It is highly scalable, low cost, as well as easy to integrate.

Medibio’s technology provides the first objective measure of stress. It provides a series of user and corporate dashboards for assessment and wellness partner interventions.

This past July, Medibio announced the appointment of The Honourable Patrick J. Kennedy to its Board of Directors. Mr. Kennedy is a former member of the U.S. House of Representatives (D-R.I.). He is the nation’s foremost political voice on mental illness, addiction, and other brain diseases.

In addition, in July, Medibio announced the appointment of Dr. Adam Darkins, MB, ChB., MPHM, M.D., FRCS to the Board of Directors as Deputy Chairman. Dr Darkins has unique experience in taking national and trans-national virtual care delivery systems to scale.

Dr Darkins developed a wide-ranging understanding of patient care, clinical processes, and outcomes measurement from his physician training at Manchester University Medical School, UK, and more training/accreditation as a neurosurgeon and researcher at UCLA (University of California, Los Angeles). 

Medibio Limited (MDBIF), closed Wednesday's trading session at $0.335, down 2.02%, on 72,501 volume with 5 trades. The average volume for the last 60 days is 10,342 and the stock's 52-week low/high is $0.25/$0.36.

SmartMetric, Inc. (SMME)

Greenbackers, SmallCapFinancialWire, Wall Street Resources, and Wall St Insider Stocks reported on SmartMetric, Inc. (SMME) and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, SmartMetric, Inc. is the developer of fingerprint authenticated and activated payments cards for use by credit and debit card issuers around the world. The Company is a technology engineering, research and development (R&D) enterprise. It has developed miniature electronic systems and software for use in the field of biometric identification and validation for the payments industry, as well as the corporate and government sectors.

SmartMetric has research and development (R&D) centers in Buenos Aires, Argentina; Palo Alto, California; and Tel-Aviv, Israel. The Company does its hardware and software engineering internally. SmartMetric has its head office in Las Vegas, Nevada.

SmartMetric, using advanced miniaturization of biometric fingerprint recognition and verification technology, can deliver portable in a card biometrics. The Company has embedded inside a credit card sized identity card a completely functional biometric fingerprint reader.

Joining the reader with miniaturized radio frequency technology inside the card provides for a premier portable biometric identity and access control solution. SmartMetric’s inventive miniature fingerprint scanner, which fits inside EMV chip credit cards, will provide an advanced biometric defense to the international payments industry.  

Regarding Biometric Payment Security, the Company’s offering brings the strength of biometrics to the domain of payments. One hundred percent identity verification with secure transaction lets the user safely buy online or offline. The card is useable at ATM machines.

Also, the card has the added security of only being able to be used after one has activated it by using their fingerprint. The SmartMetric biometric card scans and matches a person's fingerprint in under 0.25 seconds allowing for immediate card user validation. 

SmartMetric is developing a biometric activated security code display to fight online card fraud and identity theft. It is developing a credit card that has the card’s security code or “CVV number” activated following the card’s user’s fingerprint match. The SmartMetric biometric fingerprint authentication system works with EMV chip cards, with the EMV chip turned on only after a successful fingerprint scan and match with the card user. It has created a miniature fingerprint reader that is inside the credit and debit card so no other scanning device outside of the card is required to perform a biometric scan. 

As of June 2017, SmartMetric has successfully mass manufactured its biometric fingerprint activated credit card. The Company has concluded its first large scale production.

The Company’s President said, "After many years of confronting and overcoming one engineering issue after another, it is incredible for us to have finally achieved our goal in making a production credit card with our inbuilt super thin fingerprint scanner. We can now move forward with sales and marketing with card issuing financial institutions but as well adapt our biometric cards for other significantly large markets in the cyber and physical security industries."

SmartMetric, Inc. (SMME), closed Wednesday's trading session at $0.07, up 2.94%, on 20,000 volume with 1 trade. The average volume for the last 60 days is 84,690 and the stock's 52-week low/high is $0.0463/$0.1297.

Regen BioPharma, Inc. (RGBP)

TopPennyStockMovers, Wall Street Mover, ProTrader, SmallCapVoice, InvestorTrendz, and TheMicrocapNews reported on Regen BioPharma, Inc. (RGBP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Regen BioPharma, Inc. is a biotechnology company headquartered in La Mesa, California. It works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company’s aim is to speedily advance these technologies through pre-clinical and Phase I/II clinical trials. Regen BioPharma is now concentrating on checkpoint inhibitor and gene silencing therapies for treating cancer. CheckPoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Formed in 2012, Regen BioPharma lists on the OTCQB.  

The Company is also focusing  on developing stem cell treatments for aplastic anemia. Regen is presently developing products treating blood disorders employing small molecules and gene silencing (DiffronC), and treating cancer with immunotherapy (dCellVax). In essence, Regen BioPharma is working to increase the quality of life by way of therapies involving small molecules, stem cell treatments, as well as the body's own immune system.  

Furthermore, Regen is modulating important molecular processes in cancer stem cells through its patented molecular targeting approaches (BORIS). Also, the Company is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

Regen BioPharma is centering on small molecules to activate and inhibit its principal target of interest, NR2F6.The Company announced in December of 2016 the filing of a [provisional/nonprovisional] utility patent application with the United States Patents and Trademark Office (USPTO) covering NR2F6-silenced CAR T cells.

Prior work demonstrated that methodologies developed by the Company and covered under its issued patent #9,091,696 are useful in stimulation of T cell activity. Regen is continuing to develop the NR2F6 program in-house before entering into any potential partnerships.

However, the current patent further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.  CAR T cells are T Cells (T lymphocytes) that are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. CARs are proteins that permit the T cells to recognize an antigen on targeted tumor cells. 

Regen BioPharma has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

Last month, Regen BioPharma, in association with its medicinal chemistry partner, ChemDiv, Inc., announced that it believes it has made a fundamental discovery in developing small molecule drugs that activate NR2F6. It reports that recently identified novel chemical compounds, which activate NR2F6 have key structural elements that make them active and specific.
  
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen BioPharma aims to identify antagonists of NR2F6 in an effort to let loose the cancer-killing potential of a patient's own immune system and identifying agonists that should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

Regen BioPharma’s 2018 goal is to develop an activator and inhibitor of NR2F6 that is effective and not toxic in animal models.  At that point, the Company will commence experiments and process manufacturing that will enable it to apply for testing these compounds in humans.

Regen BioPharma, Inc. (RGBP), closed Wednesday's trading session at $0.03978, down 9.59%, on 307,159 volume with 21 trades. The average volume for the last 60 days is 158,877 and the stock's 52-week low/high is $0.018/$0.129.

BioSolar, Inc. (BSRC)

TheLightningPicks, HoleinOneStocks.net, Investor News Source, StockHideout, TopPennyStockMovers, PennyTrader Publisher, Stock Roach, Stock Preacher, Penny Stock Rumble, Beacon Equity Research, OTCPicks, MicroStockProfit, and BioSolar Newsletter reported previously on BioSolar, Inc. (BSRC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

BioSolar, Inc. is developing a pioneering technology to increase the storage capacity, lower the cost, and extend the life of lithium-ion batteries. The Company initially centered its development effort on high capacity cathode materials since most of contemporary Li-ion batteries are "cathode limited." With the aim of creating BioSolar’s next generation super battery technology, the Company is now investigating high capacity anode materials. BioSolar is based in Santa Clarita, California.

BioSolar is developing BioSolar supercapacitors. This is technology for decreasing the cost of storing the energy of the sun. The Company co-owns the patent-application for this supercapacitor technology with the University of California at Santa Barbara (UCSB). BioSolar is funding a sponsored research program to advance its development.  

Through integrating BioSolar supercapacitors as the high power front-end to battery banks, with fewer battery banks than would typically be needed, daytime solar energy can be quickly and cost-effectively stored for night-time use at a considerably lower cost. The technology will enable solar energy systems users to reduce their dependence or go completely off the electric utility power grid.  

BioSolar has its BioBackSheet®. The Company is the foremost commercial provider of bio-based solar panel backsheets. A backsheet is a required insulating film in all solar photovoltaic panels. Its chief purpose is to protect the solar panel components, specifically the solar cells and wires. The Company’s BioBackSheet® is the only commercially available Underwriters Laboratory (UL) certified bio-based backsheet. 
  
BioSolar management believes that use of its silicon-metal (Si-M) anode materials, now under development, can help lessen the cost of lithium-ion batteries. The expectation is that the Company’s Si-M anode material will be much less expensive than that of the benchmark silicon-carbon anode material that is the key cost issue usually associated with battery technology. The Company’s belief is that its strategy of pursuing anode material advancements to support next-generation lithium-ion batteries can play a vital role within the electric vehicle sector, and the broader energy storage technology industry. 

BioSolar announced this past June that it executed a joint development agreement with Top Battery Co., Ltd. Top Battery develops and produces lithium-ion batteries and materials for application in electric vehicles (xEV) and energy storage systems (ESS). Top Battery, based in the Republic of Korea, is a leading manufacturer of advanced lithium-ion battery solutions.

Recently, BioSolar announced successful internal tests of a proprietary additive, which can improve the performance of silicon anodes in general.  The Company has developed an additive material to enhance the performance of its Si anode for high power/fast charging applications. Silicon (Si) is one of the most promising anode materials undergoing consideration for next generation, high energy and high power lithium ion batteries.

Last month, BioSolar announced that it extended the funding of a sponsored research program at the North Carolina Agricultural and Technical State University to support the next phase of its silicon anode material technology development. The Company’s research program with North Carolina Agricultural and Technical State University initially started in September of 2016 with a concentration on low cost and high performance materials for next generation lithium-ion batteries.

BioSolar, Inc. (BSRC), closed Wednesday's trading session at $0.0428, even for the day, on 12 volume with 1 trade. The average volume for the last 60 days is 102,226 and the stock's 52-week low/high is $0.0331/$0.10.

graphic

The QualityStocks
Company Corner

graphic
graphic

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.8388, up 7.68%, on 394,031 volume with 327 trades. The stock’s average daily volume over the past 60 days is 143,029 and its 52-week low/high is $0.6171/$0.90.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ABcann Global (TSX VENTURE: ABCN) (OTCQB: ABCCF), a client of NNW that is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. The publication, titled, "Demand Outpacing Supply as Canadian Cannabis Legalization Looms," highlights the licensed producers that are gearing up for a projected spike in demand. To view the full publication, visit: https://www.networknewswire.com/demand-outpacing-supply-canadian-cannabis-legalization-looms/

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication Discussing How Licensed Canadian Cannabis Producers are Preparing for Industry Forecasts

NetworkNewsWire Announces Publication on Investment Opportunities in Canada's Cannabis Market

ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.066025, off by 5.54%, on 5,356,009 volume with 248 trades. The stock’s average daily volume over the past 60 days is 4,362,097, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc. (OTC Pink: POTN) today announces that as part of its strategy to formulate, produce and market a spectrum of exclusive and diversely targeted cannabidiol blends, the Company has appointed a new Chief Executive Officer, Richard Goulding, MD. In the Company’s effort to fortify its presence in the industry with a specialized focus, Dr. Goulding is expected to be instrumental in directing the Company’s endeavors to develop targeted formulas designed to deliver results for a diverse spectrum of challenges that studies reveal CBD can help.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

Continuing to Structure for Robust and Targeted Growth, PotNetwork Holding, Inc. Appoints Dr. Richard Goulding as New Chief Executive Officer

Diamond CBD to Sponsor Tommy Chong's Blazer's Cup Presented in San Bernadino in Partnership with Dank City LLC

PotNetwork Holding, Inc. Launches Storewide Discount on Diamond CBD Products to Support Recovery Efforts by Contributing 10% of Revenues over the Next 3 Days to Community Restoration Projects

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.06, off by 3.85%, on 4,461,919 volume with 280 trades. The stock’s average daily volume over the past 60 days is 20,609,143, and its 52-week low/high is $0.0075/$0.415.

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of CNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, "Cannabis Market Extends across Numerous Industry Segments," highlights companies that aren't directly engaged in the cannabis sector, but that stand to profit from the services and solutions offered. To view the full publication, visit: https://www.cannabisnewswire.com/cannabis-market-extends-across-numerous-industry-segments/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

CannabisNewsWire Announces Publication on Public Companies Providing Ancillary Services to the Cannabis Sector

NetworkNewsWire Announces Publication on Service Providers to the Cannabis Sector

SinglePoint Finalizes Letter of Intent to Acquire 51% of Denver-Based Company approaching $1 Million in Annual Revenue

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.9652, off by 8.66%, on 969,651 volume with 745 trades. The stock’s average daily volume over the past 60 days is 69,941, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies Inc. is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing the 3,322,375 common share purchase warrants (the "Warrants") of the Company issued in connection with a private placement offering of special warrants, which closed on July 13, 2017. The Warrants were qualified for distribution pursuant to a final short form prospectus dated August 21, 2017.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Technologies Inc. Announces Listing of Warrants

Patriot One Receives FCC Approval for PATSCAN CMR Paving Way for Commercial Roll-Out

March Networks and Patriot One Announce Integrated Video and Covert Weapon Detection Solution

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.58, up 5.45%, on 15,961 volume with 13 trades. The stock’s average daily volume over the past 60 days is 64,503 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Completes over 2,000 Surgeries at Industry Leading Surgical Institution

ORHub, Inc. Completing 2-Year Financial Audit for Advancement to the OTCQB Market

ORHub (ORHB) Announces COO Leave of Absence

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMarketWatch
(RGSE) +189.02%

2.

PoliticsAndMyPortfolio
(YECO) +77.50%

3.

Trader Power News
(STRM) +75.82%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251